Fruquintinib (Fruzaqla; also Elunate)

Fruquintinib at a glance

Fruquintinib, also called Fruzaqla, is a targeted cancer medicine taken as capsules. It interferes with signals that help a tumour develop its blood supply. Your oncologist decides whether its likely benefits outweigh the risks in your situation. This information supports the discussion and does not replace your prescription.

Elunate is another verified fruquintinib brand, used in China. This guide uses the current Fruzaqla prescribing information; follow the exact instructions for your dispensed product and any accompanying treatment.

The usual schedule is one dose each day for three weeks, followed by one week without fruquintinib. You need regular blood-pressure checks, blood tests and urine tests even when you feel well. Side effects can often be managed with supportive treatment, a pause or a lower dose.

How fruquintinib works

A growing tumour needs oxygen and nutrients carried by blood. One way it encourages new blood vessels to form is through vascular endothelial growth factor, or VEGF. Fruquintinib blocks signalling through three VEGF receptors, called VEGFR-1, VEGFR-2 and VEGFR-3. Receptors are proteins that receive signals; blocking their activity can interfere with the tumour's blood supply. This approach is called anti-angiogenic treatment.

Fruquintinib is a small-molecule kinase inhibitor. It is not conventional chemotherapy or an immune checkpoint inhibitor. However, normal blood vessels and tissue repair also depend on these signalling pathways. That helps explain why monitoring blood pressure, bleeding, urine protein and wound healing is central to its safe use.

Treatment may slow cancer growth, but benefit is not guaranteed. The number or severity of side effects cannot tell you whether the medicine is working.

How the team decides whether it is suitable

Your team considers your diagnosis, previous treatments, scans, symptoms, physical strength and treatment priorities. Relevant tumour-test results help place fruquintinib within the wider treatment plan. The medicine is not selected by finding a particular VEGFR mutation in the way some other targeted medicines require a specific gene change.

Tell the team about high blood pressure, previous heart attack or stroke, blood clots, bleeding, bowel problems, kidney or liver disease, infection and wounds that have not healed. Recent clotting events need particular attention. European information advises avoiding a new start after a clot within six months, or a stroke or transient ischaemic attack within twelve months; a transient ischaemic attack is a brief episode of stroke-like symptoms. Your oncologist applies the relevant prescribing guidance to your history.

Pre-existing liver disease needs an individual assessment. European guidance permits the usual starting dose in moderate impairment; US guidance says this group is insufficiently studied. Both advise against use in severe liver impairment. Safety and effectiveness below age 18 are not established.

Before treatment starts

Blood pressure should be controlled before the first dose. Bring a list of your medicines, including blood-pressure tablets, blood thinners, painkillers, supplements and herbal products. Mention any aspirin-related allergy or previous reaction to medicine colourings.

Baseline checks usually include blood counts, liver and kidney function, urine protein and blood pressure. Thyroid blood tests are also arranged as part of monitoring because an underactive thyroid can develop. Pregnancy testing is needed when relevant. Treatment should not start during an active infection under US guidance. Mention any infection, operation, dental extraction or recent surgery.

Before going home, make sure you understand the dose in milligrams, the capsule strength, the last treatment day and the first day of the next cycle. Ask for written advice about high home blood-pressure readings, diarrhoea and whom to contact out of hours. If you already have a stoma, discuss how to recognise an important change in its output.

How to take fruquintinib

The treatment cycle

The usual adult starting dose is 5 mg once daily on days 1–21 of a 28-day cycle, followed by no fruquintinib on days 22–28. Take it at approximately the same time each treatment day, with or without food. This is a reference schedule, not an instruction to change your prescription.

Capsules come in 1 mg and 5 mg strengths. A prescribed reduction to 4 mg means four 1 mg capsules; 3 mg means three 1 mg capsules. Do not cut up a 5 mg capsule to make a smaller dose. The oncologist may delay the next cycle or stop treatment if adverse effects cannot be managed.

Use a calendar to distinguish treatment days from rest days. Do not extend the three-week treatment period to replace missed doses, and do not restart a paused cycle without the team's instructions.

Swallowing, missed doses and vomiting

Swallow capsules whole with water. Do not open, chew, crush or dissolve them. The official information does not provide a home preparation method for a feeding tube. Contact the pharmacist before treatment if swallowing is difficult.

If you miss a dose, take it only if less than 12 hours have passed since its scheduled time. Otherwise skip it and take the next dose at the scheduled time. Never take two doses on the same day to make up for a missed dose. If uncertain about the timing, check with the treatment team.

If you vomit after a dose, do not take a replacement dose. Continue with the next scheduled dose. Repeated vomiting, inability to keep fluids down or an accidental extra dose needs prompt medical advice.

Storage and handling

Keep capsules in their original packaging, securely closed and away from children. Follow your pack's storage instructions: the US label specifies 20–25°C (68–77°F), with brief permitted excursions; European packs require protection from moisture without a special temperature condition. Ask the pharmacist about storage in very hot weather. Return unused capsules through the pharmacy's disposal system rather than putting them in household waste or wastewater.

Monitoring and checking whether treatment is working

Blood pressure can rise early and may cause no symptoms. The US label recommends checks weekly during the first month, then at least monthly, with additional checks when needed. Your team may teach you to use a home monitor. Record results and symptoms, but do not independently change either fruquintinib or blood-pressure medicines.

Urine testing looks for protein leaking through the kidneys. A positive screening test may lead to a more detailed measurement, sometimes using a timed urine collection. Significant protein loss can require a treatment pause and lower dose; severe kidney protein loss called nephrotic syndrome requires stopping the medicine.

Liver tests are checked before treatment and periodically afterwards. Blood counts, kidney function, salts such as potassium and thyroid tests help identify other effects. There is no single test schedule suitable for everyone; abnormal results or illness can mean more frequent checks.

Scans and clinical assessments measure benefit. The team also considers appetite, weight, pain, daily activities and whether side effects are acceptable. A dose reduction is a safety adjustment, not evidence that treatment has failed. Tell the team what matters most to your everyday life when discussing whether to continue.

Common side effects and practical management

You will not necessarily experience all these effects. Report changes early, especially if they interfere with eating, walking or normal activities.

High blood pressure

Take prescribed blood-pressure medicines consistently. Headache, dizziness or blurred vision needs prompt advice, but feeling well does not replace measurements. A severe headache with confusion, chest pain, visual loss or neurological changes is an emergency. Treatment may need to be paused or stopped if blood pressure is dangerously high or cannot be controlled.

Sore hands and feet

Hand-foot skin reaction can cause tenderness, redness, swelling, thickened skin or blisters on the palms and soles. Early discomfort may appear at pressure points before obvious skin changes. Examine your feet regularly and tell the team before pain makes walking difficult.

Use the moisturiser recommended by your team, comfortable shoes and protection from friction and excessive heat. Do not cut blisters or hard skin yourself. Painful or blistered skin may require prescribed treatment and a temporary interruption; simply enduring it can make recovery harder.

Diarrhoea and reduced appetite

Record loose stools or increased stoma output compared with your usual pattern. Use anti-diarrhoea medicine according to your treatment plan. Take small, frequent drinks and meals that you tolerate, while following any fluid restriction already prescribed. Contact the team promptly if diarrhoea continues, you cannot drink, or you become dizzy or pass much less urine.

Severe or persistent abdominal pain, blood in stool or a swollen tender abdomen needs urgent assessment rather than repeated self-treatment for diarrhoea. Ask for dietary support if appetite or weight is falling.

Tiredness, thyroid changes and voice changes

Fatigue can affect concentration and stamina. Alternate activity with rest and tell the team if the change is marked. An underactive thyroid can contribute to tiredness, feeling cold, constipation, weight gain or changes in skin and hair. Blood tests distinguish this from other causes; thyroid replacement medicine may help.

A hoarse or altered voice can occur. Report persistent symptoms, particularly if speaking or swallowing becomes difficult. Breathing difficulty should not be attributed to a harmless voice change.

Mouth discomfort, pain and blood-test changes

Mouth soreness or ulcers can make eating difficult. Use gentle mouth care and ask about suitable rinses and pain relief. Tell the team if you cannot eat or drink normally. Muscle or joint pain can also occur; have painkillers checked before taking them.

Platelet counts may fall, increasing bruising or bleeding. Liver enzymes and urine protein can change without visible symptoms. Keeping test appointments matters even when troublesome side effects are absent.

Important side effects

Bleeding, clots and major blood-vessel problems

Bleeding can occur from the nose or gums, but internal bleeding can be serious or fatal. Report new unexplained bruising or repeated bleeding. Vomiting blood, black tar-like stool, significant rectal bleeding or faintness with bleeding needs emergency assessment. Risk assessment is especially important if you take a blood thinner.

Clots in arteries can interrupt blood flow to the brain or heart. Sudden weakness, facial drooping, speech difficulty or chest pain needs emergency help. A painful swollen leg also needs urgent assessment, particularly with breathlessness. Arterial thrombosis requires discontinuation; European guidance calls for stopping immediately if it is suspected.

Current European information lists aortic dissection, a tear in the wall of the body's main artery, reported after marketing. Its frequency cannot be estimated. Sudden severe chest, back or abdominal pain is an emergency. This warning does not mean ordinary mild aches are a dissection, but sudden severe pain must not be watched at home.

Bowel perforation, fistula and abdominal inflammation

A hole in the stomach or bowel wall is called a gastrointestinal perforation. An abnormal connection between organs or to the skin is a fistula. These can be dangerous and may require surgery. Severe, persistent or worsening abdominal pain, fever, vomiting or bleeding needs urgent assessment. Confirmed perforation or fistula requires permanent discontinuation under US prescribing guidance.

Inflammation of the pancreas or gallbladder is also reported. Persistent upper abdominal pain, particularly with vomiting or fever, should be assessed rather than assumed to be indigestion.

Liver injury, infection and kidney problems

Contact the team urgently for yellow skin or eyes, dark urine, marked nausea or pain under the right ribs. Severe liver injury has occurred. Urine protein loss may produce frothy urine or swelling; report these, and any substantial reduction in urine. Blood and urine tests guide treatment changes. Thrombotic microangiopathy, small-vessel clotting that can damage kidneys and blood cells, has also been reported; reduced urine with unusual bruising or marked weakness needs urgent assessment.

Serious infections can occur, sometimes with reduced white blood cells. Fever, shivering, cough, painful urination or suddenly feeling very unwell needs prompt advice. Serious infection is possible even with a normal temperature. Serious or worsening infection requires a treatment hold until resolved under US guidance.

PRES and allergic reactions

Posterior reversible encephalopathy syndrome, or PRES, is a serious brain condition involving swelling. Symptoms can include seizures, severe headache, confusion, drowsiness or visual changes. Emergency assessment and brain imaging are needed; fruquintinib is stopped when PRES develops. Although “reversible” is in the name, urgent treatment is essential.

Capsule colourings can cause allergic reactions. The 1 mg strength contains tartrazine and sunset yellow; European information also warns about Allura red in the 5 mg strength. Mention known colourant allergies and aspirin-related hypersensitivity. Swelling of the face or throat, wheezing or breathing difficulty requires emergency help.

Wound healing and operations

Fruquintinib can slow healing. The US label specifies withholding it for at least two weeks before major surgery, and for at least two weeks afterwards and until adequate healing. European information gives a minimum two-week interval before and after surgery more generally. Your surgeon and oncologist must agree the actual plan.

Tell them about dental extractions and any procedure involving a wound. Do not restart simply because two weeks have elapsed. Report a wound that opens, leaks or becomes increasingly painful or red.

Other medicines, supplements and vaccinations

Some medicines speed up the breakdown of fruquintinib and may make it less effective. A key example is rifampicin, used for tuberculosis and other infections. Strong and moderate CYP3A inducers should be avoided. US guidance allows an unavoidable moderate inducer with the usual prescribed fruquintinib dose; this requires specialist review. “CYP3A” refers to one of the body's medicine-processing systems. Do not stop an essential medicine yourself; have the oncology pharmacist check the combination.

Not every interaction rule for another targeted tablet applies here. Studies did not find a clinically meaningful effect from the acid-reducing medicine rabeprazole or the strong CYP3A inhibitor itraconazole. European information does not require a fruquintinib adjustment for acid-lowering medicines or CYP3A inhibitors. This does not remove the need to check your full medication list.

Blood thinners, aspirin and anti-inflammatory painkillers need review because bleeding matters. Warfarin may require closer INR testing, which measures its blood-thinning effect. Do not start herbal remedies or supplements without checking them. Discuss vaccines with the team; suitability depends on the vaccine, blood counts and other treatments, particularly for live vaccines.

Everyday life during treatment

Plan demanding activities around your energy and symptoms rather than assuming the rest week will always be symptom-free. Gentle activity can help maintain function, but protect sore feet from pressure. Adjust work hours if fatigue or hand discomfort makes usual tasks difficult.

Do not drive or operate machinery when tiredness, dizziness, vision problems or poor concentration could make it unsafe. Discuss travel before booking so that medicine supplies, blood-pressure checks and test appointments remain covered. Carry treatment details and know where to obtain urgent help away from home.

Use routine hand hygiene and avoid close contact with people who are clearly unwell. Tell your dentist about fruquintinib before treatment. Sex and intimacy can continue if comfortable, with the pregnancy precautions below. Speak to your team about worry, low mood or practical strain; support is part of treatment, not something reserved for a crisis.

Fertility, contraception, pregnancy and breastfeeding

Fruquintinib can harm an unborn baby. Discuss pregnancy intentions before starting and contact the team promptly if pregnancy occurs or is suspected. When you can become pregnant, use effective contraception throughout treatment and for at least two weeks after the last dose; European information specifies a highly effective method.

US information also instructs men with partners who could become pregnant to use effective contraception during treatment and for two weeks afterwards. Confirm the method with the team. A longer restriction from another medicine still applies; the fruquintinib interval does not shorten it.

Do not breastfeed during treatment or for two weeks after the final dose. Ask about a suitable feeding plan. Effects on human fertility are not established, but animal findings raise concern. Discuss fertility preservation before treatment if future parenthood matters to you.

After treatment finishes

Continue follow-up for unresolved blood-pressure, kidney, liver, thyroid or skin effects. Do not independently stop blood-pressure or thyroid medicines when fruquintinib stops; the team reviews whether they remain necessary.

Keep following the contraception and breastfeeding intervals, and make sure surgeons know your last dose date. Return unused medicine safely. Your oncologist will discuss the next treatment or supportive-care plan in the context of your priorities and current health. Urgent symptoms still need assessment after the final capsule.

Frequently asked questions